Predicting the impact of single-nucleotide polymorphisms in CDK2-flavopiridol complex by molecular dynamics analysis
- PMID: 23300027
- DOI: 10.1007/s12013-012-9512-5
Predicting the impact of single-nucleotide polymorphisms in CDK2-flavopiridol complex by molecular dynamics analysis
Abstract
Cyclic-dependent kinase 2 (CDK2) is one of the primary protein kinases involved in the regulation of cell cycle progression. Flavopiridol is a flavonoid derived from an indigenous plant act as a potent antitumor drug showing increased inhibitory activity toward CDK2. The presence of deleterious variations in CDK2 may produce different effects in drug-binding adaptability. Studies on nsSNPs of CDK2 gene will provide information on the most likely variants associated with the disease. Furthermore, investigating the relationship between deleterious variants and its ripple effect in the inhibitory action with drug will provide fundamental information for the development of personalized therapies. In this study, we predicted four variants Y15S, V18L, P45L, and V69A of CDK2 as highly deleterious. Occurrence of these variations seriously affected the normal binding capacity of flavopiridol with CDK2. Analysis of 10-ns molecular dynamics (MD) simulation trajectories indicated that the predicted deleterious variants altered the CDK2 stability, flexibility, and surface area. Notably, we noticed the decrease in number of hydrogen bonds between CDK2 and flavopiridol mutant complexes in the whole dynamic period. Overall, this study explores the possible relationship between the CDK2 deleterious variants and the drug-binding ability with the help of molecular docking and MD approaches.
Similar articles
-
Extrapolating the effect of deleterious nsSNPs in the binding adaptability of flavopiridol with CDK7 protein: a molecular dynamics approach.Hum Genomics. 2013 Apr 5;7(1):10. doi: 10.1186/1479-7364-7-10. Hum Genomics. 2013. PMID: 23561625 Free PMC article.
-
Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.J Theor Biol. 2013 Oct 7;334:87-100. doi: 10.1016/j.jtbi.2013.05.014. Epub 2013 May 29. J Theor Biol. 2013. PMID: 23727278
-
Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.Cancer Res. 1996 Jul 1;56(13):2973-8. Cancer Res. 1996. PMID: 8674031
-
Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach.Adv Protein Chem Struct Biol. 2016;102:267-97. doi: 10.1016/bs.apcsb.2015.09.008. Epub 2015 Oct 29. Adv Protein Chem Struct Biol. 2016. PMID: 26827608 Review.
-
Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors.Future Med Chem. 2009 Nov;1(8):1453-66. doi: 10.4155/fmc.09.102. Future Med Chem. 2009. PMID: 21426059 Review.
Cited by
-
Marmesin and Marmelosin Interact with the Heparan Sulfatase-2 Active Site: Potential Mechanism for Phytochemicals from Bael Fruit Extract as Antitumor Therapeutics.Oxid Med Cell Longev. 2023 Jan 5;2023:9982194. doi: 10.1155/2023/9982194. eCollection 2023. Oxid Med Cell Longev. 2023. PMID: 36644581 Free PMC article.
-
A study of genomic diversity in populations of Maharashtra, India, inferred from 20 autosomal STR markers.BMC Res Notes. 2021 Feb 23;14(1):69. doi: 10.1186/s13104-021-05485-z. BMC Res Notes. 2021. PMID: 33622409 Free PMC article.
-
Analysing the Effect of Mutation on Protein Function and Discovering Potential Inhibitors of CDK4: Molecular Modelling and Dynamics Studies.PLoS One. 2015 Aug 7;10(8):e0133969. doi: 10.1371/journal.pone.0133969. eCollection 2015. PLoS One. 2015. PMID: 26252490 Free PMC article.
-
Integrating in silico prediction methods, molecular docking, and molecular dynamics simulation to predict the impact of ALK missense mutations in structural perspective.Biomed Res Int. 2014;2014:895831. doi: 10.1155/2014/895831. Epub 2014 Jun 26. Biomed Res Int. 2014. PMID: 25054154 Free PMC article.
-
Identification of natural inhibitor against L1 β-lactamase present in Stenotrophomonas maltophilia.J Mol Model. 2022 Oct 5;28(11):342. doi: 10.1007/s00894-022-05336-z. J Mol Model. 2022. PMID: 36197525 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous